https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2/2019-04-09T08:00:45+00:00https://bokhee.kim/zynquista-sotagliflozin-new-add-on-treatment-to-insulin-for-treatment-of-certain-patients-with-type-1-diabetes/2019-03-04T09:00:20+00:00https://bokhee.kim/palynziq-pegvaliase-new-treatment-for-phenylketonuria-a-rare-inherited-metabolic-disease/2019-03-04T09:30:36+00:00https://bokhee.kim/waylivra-volanesorsen-first-treatment-for-rare-disease-characterised-by-high-levels-of-triglycerides-in-blood/2019-03-04T10:00:25+00:00https://bokhee.kim/ondexxya-andexanet-alfa-first-antidote-for-reversal-of-anticoagulation-with-factor-xa-inhibitors-apixaban-and-rivaroxaban/2019-03-04T10:30:41+00:00https://bokhee.kim/new-indication-for-dupixent-dupilumab-as-add-on-treatment-for-patients-with-severe-asthma/2019-03-04T11:00:21+00:00https://bokhee.kim/fda-approves-new-nasal-spray-medication-for-treatment-resistant-depression-available-only-at-a-certified-doctors-office-or-clinic/2019-03-12T09:00:47+00:00https://bokhee.kim/merck-has-announced-the-fda-approval-of-its-mavenclad-cladribine-tablets-in-various-forms-of-multiple-sclerosis-ms/2019-04-01T08:00:19+00:00https://bokhee.kim/zynteglo-new-gene-therapy-to-treat-rare-inherited-blood-condition/2019-04-02T08:00:58+00:00https://bokhee.kim/mayzent-siponimod-tablets-approved-by-fda-to-treat-adults-with-relapsing-forms-of-multiple-sclerosis-ms/2019-04-03T08:00:39+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2/2019-04-17T08:00:50+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2/2019-04-27T08:00:27+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2/2019-05-07T08:00:29+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2-2/2019-05-18T08:00:22+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2-2-2/2019-05-26T08:00:18+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2-2-2-2/2019-05-31T08:00:19+00:00https://bokhee.kim/zynquista-sotagliflozin-new-add-on-treatment-to-insulin-for-treatment-of-certain-patients-with-type-1-diabetes-2/2019-02-18T09:00:43+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2-2-2-2-2/2019-02-10T09:00:20+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2-2-2-2-3/2019-02-07T09:00:07+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2-2-2-2-4/2019-01-25T09:30:00+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2-2-2-2-5/2019-01-25T09:00:44+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2-2-2-2-6/2019-01-11T09:00:56+00:00https://bokhee.kim/dovato-dolutegravir-and-lamivudine-a-new-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment-2-2-2-2-2-2-2-7/2019-01-07T09:00:20+00:00https://bokhee.kim/fda-approves-xpovio-selinexor-new-treatment-for-refractory-multiple-myeloma/2019-07-10T08:15:37+00:00https://bokhee.kim/fda-approves-soliriseculizumab-first-treatment-for-neuromyelitis-optica-spectrum-disorder-a-rare-autoimmune-disease-of-the-central-nervous-system/2019-07-10T08:29:23+00:00https://bokhee.kim/victoza-liraglutide-new-treatment-for-children-with-type-2-diabetes/2019-07-17T06:33:06+00:00https://bokhee.kim/dupixent-dupilumab-first-treatment-for-chronic-rhinosinusitis-with-nasal-polyps/2019-07-16T07:43:22+00:00https://bokhee.kim/baqsimi-nasal-powder-glucagon-first-treatment-for-severe-hypoglycemia-that-can-be-administered-without-an-injection/2019-08-15T09:37:16+00:00https://bokhee.kim/vitrakvi-larotrectinib-first-histology-independent-treatment-for-solid-tumours-with-a-specific-gene-mutation/2019-08-09T06:55:04+00:00https://bokhee.kim/pretomanid-new-drug-for-the-treatment-of-tuberculosis-that-affects-the-lungs/2019-08-17T09:58:38+00:00https://bokhee.kim/inrebic-fedratinib-capsules-new-treatment-for-adult-patients-with-certain-types-of-myelofibrosis/2019-08-22T17:37:05+00:00https://bokhee.kim/xenleta-lefamulin-new-antibiotic-to-treat-community-acquired-bacterial-pneumonia/2019-08-31T16:46:43+00:00https://bokhee.kim/nourianz-istradefylline-new-add-on-drug-to-treat-off-episodes-in-adults-with-parkinsons-disease/2019-09-07T17:13:52+00:00https://bokhee.kim/ofev-nintedanib-first-treatment-for-patients-with-rare-type-of-lung-disease/2019-09-23T07:48:38+00:00https://bokhee.kim/rybelsus-semaglutide-first-oral-glp-1-treatment-for-type-2-diabetes/2019-09-24T11:57:38+00:00https://bokhee.kim/mavyret-glecaprevir-and-pibrentasvir-a-treatment-for-adults-and-children-with-all-genotypes-of-hepatitis-c-and-compensated-cirrhosis-shortens-the-duration-of-treatment-to-eight-weeks/2019-10-01T12:56:22+00:00https://bokhee.kim/trikafta-elexacaftor-ivacaftor-tezacaftor-new-breakthrough-therapy-for-cystic-fibrosis/2019-11-04T08:01:38+00:00https://bokhee.kim/reyvow-lasmiditan-new-treatment-for-patients-with-migraine/2019-11-05T13:56:22+00:00https://bokhee.kim/descovy-emtricitabine-and-tenofovir-alafenamide-drug-to-prevent-hiv-infection/2019-11-20T11:46:02+00:00https://bokhee.kim/ervebo-first-vaccine-to-protect-against-ebola/2019-11-19T14:26:50+00:00https://bokhee.kim/baqsimi-glucagon-first-non-injectable-treatment-for-severe-low-blood-sugar-levels/2019-11-12T14:05:16+00:00https://bokhee.kim/misight-first-contact-lens-indicated-to-slow-the-progression-of-nearsightedness-in-children/2019-11-26T14:15:53+00:00https://bokhee.kim/first-generics-of-gilenya-fingolimod-capsules-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis-ms/2019-12-11T10:09:55+00:00https://bokhee.kim/phorbiplatin-a-new-on-site-activated-anti-tumor-prodrug-that-effectively-kills-cancer-cells-minimizing-damage-to-normal-tissues/2020-01-09T11:04:33+00:00https://bokhee.kim/enhertu-fam-trastuzumab-deruxtecan-nxki-new-treatment-option-for-patients-with-her2-positive-breast-cancer-who-have-progressed-on-available-therapies/2020-01-15T18:11:34+00:00https://bokhee.kim/padcev-enfortumab-vedotin-ejfv-a-new-type-of-therapy-to-treat-advanced-urothelial-cancer/2020-01-13T11:41:42+00:00https://bokhee.kim/lynparza-olaparib-already-licensed-for-breast-and-ovarian-cancerits-set-to-become-the-worlds-first-precision-medicine-for-prostate-cancer/2020-01-09T11:49:49+00:00https://bokhee.kim/the-combination-of-lopinavir-ritonavir-and-interferon-beta-1b-shows-good-results-against-the-middle-east-respiratory-syndrome-coronavirus-mers-cov/2020-01-23T15:41:20+00:00https://bokhee.kim/fda-approves-first-drug-for-treatment-of-peanut-allergy-for-children/2020-02-03T08:39:16+00:00https://bokhee.kim/givlaari-givosiran-first-treatment-for-acute-hepatic-porphyria/2020-02-05T12:45:23+00:00https://bokhee.kim/first-cardiac-ultrasound-software-that-uses-artificial-intelligence-to-guide-user/2020-02-09T18:06:09+00:00https://bokhee.kim/fda-grants-priority-review-for-kites-kte-x19-biologics-license-application-bla-in-relapsed-or-refractory-mantle-cell-lymphoma/2020-02-11T15:58:09+00:00https://bokhee.kim/fda-authorizes-marketing-of-the-first-genetic-test-to-aid-in-the-diagnosis-of-fragile-x-syndrome/2020-02-22T17:34:29+00:00https://bokhee.kim/ofatumumab-the-new-potential-first-choice-treatment-for-relapsing-forms-of-multiple-sclerosis/2020-02-28T10:20:02+00:00https://bokhee.kim/sarclisa-isatuximab-irfc-new-therapy-for-patients-with-previously-treated-multiple-myeloma/2020-03-03T13:15:56+00:00https://bokhee.kim/koselugo-selumetinib-newly-approved-treatment-of-neurofibromatosis-type-1-nf1/2020-04-13T11:27:30+00:00https://bokhee.kim/tukysa-tucatinib-new-option-of-treatment-of-adult-patients-with-advanced-forms-of-her2-positive-breast-cancer/2020-04-18T13:12:20+00:00https://bokhee.kim/menquadfi-is-sanofis-latest-vaccine-for-the-prevention-of-invasive-meningococcal-disease-menacwy/2020-04-27T10:42:54+00:00https://bokhee.kim/novartis-announces-fda-approval-of-met-inhibitor-tabrecta-for-metastatic-non-small-cell-lung-cancer-with-metex14/2020-05-11T14:54:21+00:00https://bokhee.kim/qinlock-ripretinib-is-the-first-drug-for-fourth-line-treatment-of-advanced-gastrointestinal-stromal-tumors/2020-05-19T09:08:03+00:00https://bokhee.kim/fda-approves-oriahnn-an-estrogen-and-progestin-combination-product-consisting-of-elagolix-estradiol-and-norethindrone-acetateto-treat-heavy-menstrual-bleeding-associated-with-fibroids-in-women/2020-05-29T18:48:35+00:00https://bokhee.kim/fda-approves-mercks-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-hospital-acquired-and-ventilator-associated-bacterial-pneumonia-habp-vabp/2020-06-06T08:58:29+00:00https://bokhee.kim/uplizna-inebilizumab-cdontherapy-for-neuromyelitis-optica-spectrum-disorder-offers-patients-additional-treatment-option/2020-06-12T08:12:01+00:00https://bokhee.kim/rukobia-fostemsavir-a-new-antiretroviral-medication-for-patients-who-have-run-out-of-hiv-treatment-options/2020-07-07T07:47:44+00:00https://bokhee.kim/inqovi-decitabine-and-cedazuridine-new-therapy-for-myelodysplastic-syndromes-mds-that-can-be-taken-at-home/2020-07-14T08:37:10+00:00https://bokhee.kim/blenrep-belantamab-mafodotin-new-option-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma/2020-07-24T13:17:37+00:00https://bokhee.kim/vaginal-ring-to-reduce-the-risk-of-hiv-infection-for-women-in-non-eu-countries-with-high-disease-burden/2020-08-14T15:52:00+00:00https://bokhee.kim/rozlytrek-roches-first-tumour-agnostic-therapy-approved-in-europe-for-people-with-ntrk-fusion-positive-solid-tumours-and-for-people-with-ros1-positive-advanced-non-small-cell-lung-cancer/2020-08-14T15:47:46+00:00https://bokhee.kim/roche-announces-fda-approval-of-foundationone-liquid-cdx-a-comprehensive-pan-tumour-liquid-biopsy-test/2020-08-29T16:09:07+00:00https://bokhee.kim/new-indication-for-olumiant-baricitinib-as-oral-treatment-for-moderate-to-severe-atopic-dermatitis/2020-09-18T16:00:04+00:00https://bokhee.kim/velphoro-sucroferric-oxyhydroxide-has-been-approved-for-the-treatment-of-children-with-chronic-kidney-disease/2020-09-21T16:36:12+00:00https://bokhee.kim/1485-2/2020-09-27T16:01:19+00:00https://bokhee.kim/jyseleca-filgotinib-approved-in-the-eu-for-the-treatment-of-adults-with-moderate-to-severe-rheumatoid-arthritis/2020-10-02T13:19:17+00:00https://bokhee.kim/opdivo-nivolumab-in-combination-with-yervoy-ipilimumab-newly-approved-as-first-line-treatment-of-adults-with-malignant-pleural-mesothelioma/2020-10-05T12:51:23+00:00https://bokhee.kim/inmazeb-atoltivimab-maftivimab-and-odesivimab-ebgn-first-fda-approved-treatment-for-ebola-virus/2020-10-15T14:53:44+00:00https://bokhee.kim/rekambys-rilpivirine-and-vocabria-injection-cabotegravir-first-long-acting-injectable-antiretroviral-therapy-for-hiv/2020-10-21T19:00:31+00:00https://bokhee.kim/new-indication-expands-use-of-brilinta-ticagrelor-beyond-cardiovascular-disease-to-patients-with-mild-to-moderate-stroke/2020-11-09T19:32:55+00:00https://bokhee.kim/zokinvy-lonafarnib-is-the-first-approved-treatment-for-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies/2020-11-24T20:05:07+00:00https://bokhee.kim/european-commission-approves-janssens-tremfya-guselkumab-a-first-in-class-treatment-for-active-psoriatic-arthritis-psa/2020-11-26T19:10:28+00:00https://bokhee.kim/gallium-68-psma-11-ga-68-psma-11is-the-first-psma-targeted-pet-imaging-drug-for-men-with-prostate-cancer/2020-12-03T14:53:25+00:00https://bokhee.kim/tagrisso-osimertinib-first-adjuvant-therapy-for-most-common-type-of-lung-cancer/2020-12-19T07:54:00+00:00https://bokhee.kim/of-palforzia-defatted-powder-of-arachis-hypogaea-l-semen-peanuts-for-the-treatment-of-peanut-allergy/2020-12-21T11:18:03+00:00https://bokhee.kim/libmeldy-worlds-first-lentiviral-vector-based-gene-therapy-for-the-treatment-of-metachromatic-leukodystrophy-mld/2020-12-22T10:10:17+00:00https://bokhee.kim/ibrance-palbociclib-is-the-1-prescribed-fda-approved-oral-combination-treatment-for-hr-her2-mbc/2021-01-05T14:49:04+00:00https://bokhee.kim/glucagon-for-injection-usp-first-generic-of-drug-used-to-treat-severe-hypoglycemia/2021-01-08T16:01:47+00:00https://bokhee.kim/xofluza-baloxavir-marboxil-a-first-in-class-single-dose-oral-medicine-for-the-treatment-of-influenza/2021-01-12T18:39:52+00:00https://bokhee.kim/enhertu-trastuzumab-deruxtecan-first-her2-directed-medicine-approved-in-a-decade-for-patients-with-her2-positive-metastatic-gastric-cancer/2021-01-18T17:36:13+00:00https://bokhee.kim/xalkori-crizotinib-approved-for-alk-positive-anaplastic-large-cell-lymphoma-in-children-and-young-adults/2021-01-19T17:59:48+00:00https://bokhee.kim/rinvoq-upadacitinib-approved-for-the-treatment-of-psoriatic-arthritis-and-ankylosing-spondylitis/2021-01-26T11:44:30+00:00https://bokhee.kim/breyanzi-lisocabtagene-maraleucel-new-treatment-for-adults-with-relapsed-or-refractory-large-b-cell-lymphoma/2021-02-09T20:26:57+00:00https://bokhee.kim/cosela-trilaciclib-first-therapy-in-its-class-to-reduce-the-frequency-of-chemotherapy-induced-bone-marrow-suppression/2021-02-14T15:53:09+00:00https://bokhee.kim/evrysdi-risdiplam-first-oral-treatment-for-spinal-muscular-atrophy-sma/2021-02-27T14:19:08+00:00https://bokhee.kim/arcalyst-is-the-first-fda-approved-therapy-for-recurrent-pericarditis/2021-03-23T20:43:12+00:00https://bokhee.kim/abecma-idecabtagene-vicleucel-first-cell-based-gene-therapy-for-adult-patients-with-multiple-myeloma/2021-04-03T14:39:26+00:00https://bokhee.kim/novartis-receives-eu-approval-for-kesimpta-ofatumumab-the-first-and-only-self-administered-targeted-b-cell-therapy-for-adult-patients-with-relapsing-multiple-sclerosis/2021-04-17T09:18:35+00:00https://bokhee.kim/enspryng-satralizumab-new-treatment-for-rare-autoimmune-disease-of-nerve-cells/2021-04-27T14:19:31+00:00https://bokhee.kim/farxiga-dapagliflozin-approved-for-the-treatment-of-chronic-kidney-disease/2021-05-03T18:54:02+00:00https://bokhee.kim/lumakras-sotorasib-as-the-first-treatment-for-adult-patients-with-non-small-cell-lung-cancer-whose-tumors-have-a-specific-type-of-genetic-mutation-called-kras-g12c/2021-06-01T08:22:07+00:00https://bokhee.kim/1566-2/2021-06-07T14:05:33+00:00https://bokhee.kim/aduhelm-aducanumab-first-new-alzheimers-drug-in-20-years/2021-06-08T07:40:22+00:00https://bokhee.kim/astepro-azelastine-hydrochloride-nasal-spray-0-15-nasal-antihistamine-approved-for-nonprescription-use/2021-06-18T08:14:32+00:00https://bokhee.kim/byooviz-ranibizumab-nuna-first-biosimilar-to-treat-macular-degeneration-disease-and-other-eye-conditions/2021-09-21T10:56:42+00:00https://bokhee.kim/trodelvy-sacituzumab-govitecan-first-in-class-medicine-to-treat-aggressive-form-of-breast-cancer/2021-10-25T16:52:51+00:00https://bokhee.kim/cyltezoadalimumab-adbm-the-first-interchangeable-biosimilar-to-humira/2021-11-03T11:27:30+00:00https://bokhee.kim/breyanzi-lisocabtagene-maraleucel-new-gene-therapy-treatment-for-patients-with-relapsed-or-refractory-large-b-cell-lymphoma/2022-02-07T11:55:17+00:00https://bokhee.kim/jardiance-empagliflozinapproved-for-wider-range-of-patients-with-heart-failure/2022-03-11T14:43:54+00:00https://bokhee.kim/kimmtrak-tebentafusp-a-monotherapy-for-the-treatment-of-adult-patients-with-uveal-melanoma-a-rare-type-of-eye-cancer/2022-03-09T10:37:53+00:00https://bokhee.kim/carvykti-ciltacabtagene-autoleucel-new-gene-therapy-to-treat-adult-patients-with-multiple-myeloma/2022-03-30T16:28:46+00:00https://bokhee.kim/new-hope-for-the-treatment-of-neurodegenerative-diseases-including-lewy-bodies-dementia-and-parkinsons-disease/2023-03-07T11:00:53+00:00https://bokhee.kim/its-rare-disease-day/2023-02-28T11:17:35+00:00https://bokhee.kim/welcome-to-our-new-export-manager-federica/2023-02-17T14:55:40+00:00https://bokhee.kim/find-elixi-at-arab-health/2023-02-03T15:10:05+00:00https://bokhee.kim/fabio-macchi-is-our-new-head-of-medical-and-quality-departments/2023-01-16T15:12:43+00:00https://bokhee.kim/elixi-will-be-at-the-27th-eahp-the-european-association-of-hospital-pharmacists-annual-congress-from-the-22nd-to-the-24th-of-march-2023-in-lisbon-portugal/2023-03-10T15:27:15+00:00https://bokhee.kim/world-orphan-drug-congress-2023/2023-04-20T12:35:01+00:00https://bokhee.kim/first-vaccine-to-protect-older-adults-from-respiratory-syncytial-virus-rsv-infection/2023-05-02T08:39:40+00:00https://bokhee.kim/1968-2/2023-05-04T10:07:37+00:00https://bokhee.kim/2097-2/2023-05-17T17:13:14+00:00https://bokhee.kim/2104-2/2023-05-12T17:20:50+00:00https://bokhee.kim/world-thyroid-day-25th-may-2023/2023-05-23T12:24:12+00:00https://bokhee.kim/may-is-world-bladder-cancer-awareness-month/2023-05-30T13:58:38+00:00https://bokhee.kim/targeted-therapy-vorasidenib-offers-hope-for-deadly-brain-tumors/2023-06-05T10:16:48+00:00https://bokhee.kim/we-join-in-celebrating-global-wellness-day/2023-06-10T09:48:30+00:00https://bokhee.kim/a-new-class-of-medicines-to-treat-pediatric-type-2-diabetes/2023-06-25T18:46:06+00:00https://bokhee.kim/fda-approves-first-cellular-therapy-to-treat-patients-with-type-1-diabetes/2023-06-29T13:43:01+00:00https://bokhee.kim/elixi-international-is-proud-to-announce-the-opening-of-our-subsidiary-in-singapore/2023-07-04T12:59:50+00:00https://bokhee.kim/september-is-the-world-alzheimers-awareness-month-2023/2023-09-08T12:34:37+00:00https://bokhee.kim/come-and-meet-us-at-expopharm-2023-27-30-september-in-dusseldorf/2023-09-13T07:53:50+00:00https://bokhee.kim/please-join-us-in-congratulating-fabio-for-his-first-successful-year-in-elixi/2026-03-24T13:04:27+00:00https://bokhee.kim/meet-our-ai-driven-robot/2026-03-24T13:02:59+00:00https://bokhee.kim/arab-health-2025/2026-03-24T13:01:36+00:00https://bokhee.kim/basel-sga-2026/2026-03-12T17:13:39+00:00https://bokhee.kim/for-the-3-year-in-a-row-we-are-the-best/2026-03-24T12:54:33+00:00